SCHEMBL22743534

SCHEMBL22743534

Cc1ccc2cc3c(nc2c1)NCCC3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPK1 P28482 1/20 0.42
UBE2N P61088 1/20 0.42
UHRF1 Q96T88 1/20 0.41
CYP1A2 P05177 2/20 0.41
RAB9A P51151 1/20 0.37
GFER P55789 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HPGD P15428 1/20 0.36
EHMT2 Q96KQ7 1/20 0.36
NNMT P40261 1/20 0.36
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22743004 0.81 BACE1 (0.39) KMT2AMEN1UHRF1CYP1A2RAB9A
SCHEMBL22743872 0.81 UHRF1 (0.36) KMT2AMEN1UHRF1RAB9AGFER
SCHEMBL9098370 0.79 RAB9A (0.43) ALDH1A1KMT2AMEN1KDM4EGAA
SCHEMBL14852747 0.78 PARP10 (0.42) ALDH1A1KMT2AMEN1KDM4ECYP1A2
SCHEMBL22742636 0.77 EHMT2 (0.33) KMT2AMEN1UHRF1RAB9AGFER
SCHEMBL22717228 0.74 NNMT (0.35) ALDH1A1KMT2AMEN1KDM4EGAA
SCHEMBL22743496 0.74 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1KDM4EGAA
SCHEMBL4119102 0.73 NNMT (0.40) KMT2AMEN1UHRF1RAB9AGFER
SCHEMBL22742236 0.73 ALDH1A1 (0.40) ALDH1A1KMT2AMEN1KDM4EGAA
SCHEMBL20153296 0.71 UHRF1 (0.51) ALDH1A1KDM4EGAAUHRF1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020243178-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS ANGEX PHARMACEUTICAL, INC. (US) 2020-12-03 WO disclosed